陈野野;田震寰;周小昀;张晔;刘洪生;李单青;
CHEN Ye-ye;TIAN Zhen-huan;ZHOU Xiao-yun;ZHANG Ye;LIU Hong-sheng;LI Shan-qing;Department of Thoracic Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences &Peking Union Medical College;

• 1:中国医学科学院北京协和医学院北京协和医院胸外科

摘要(Abstract)：

目的探讨支气管肺类癌,包括典型类癌(typical carcinoid,TC)及不典型类癌(atypical carcinoid,ATC)的临床特点及手术治疗经验,并分析可能的预后因素。方法回顾总结2000年1月至2014年1月在北京协和医院接受手术治疗并经病理检查证实为TC或ATC的57例患者临床资料,同时进行生存和预后分析。结果 57例患者中男性35例,女性22例,中位年龄49岁(12⁸5岁),中位病程3个月(185岁),中位病程3个月(1¹56个月),临床症状缺乏特异性,12例伴有异位促肾上腺皮质激素综合征。术后病理确诊TC 39例,ATC 18例;Ⅰ期为主,共41例,Ⅱ期和Ⅲ期各7例,IV期2例。5年、10年存活率分别为92.4%及89.0%。Kaplan-Meier分析显示,病理类型、T分期及N分期的P值分别为0.001、0.000、0.004。结论支气管肺TC及ATC缺乏特异性临床表现,手术效果良好,病理分型、肿瘤T分期和N分期可能是预后的影响因素。
Objective The aim of this study was to evaluate the clinical features and the surgical experience of patients with bronchopulmonary carcinoids,including typical carcinoid( TC) and atypical carcinoid( ATC),and to analyze the potential prognostic factors. Methods From January 2000 to January 2014,the clinical data of 57 consecutive cases of bronchopulmonary undergoing surgical resection and confirmed as TC or ATC by pathology in Peking Union Medical College Hospital were retrospectively analyzed; survival and prognostic analysis were also performed. Results There were 35 males and 22 females. The median age was 49( 12-85) years old,and the median duration of disease was 3( 1-156) months. Clinical symptoms lack specificity,and 12 cases got ectopic adrenocorticotropic hormone syndrome. The postoperative pathological examination confirmed 39 cases of TC and 12 cases of ATC; staging consisted of 41 cases of stageⅠ,7 stageⅡ,7 stage Ⅲ,and 2 stage Ⅳ. The 5-year and the 10-year survival rates were 92. 4% and 89. 0%,respectively. Kaplan-Meier analysis showed that the P values of pathological type,T stage and N stage were 0. 001,0. 000 and 0. 004,respectively. Conclusions The clinical features of bronchopulmonary TC and ATC are atypical and these patients have a preferably prognosis after surgery.Pathological types,T stages,and N stages might be the prognostic factors.

关键词(KeyWords)： 神经内分泌癌;肺;手术治疗;预后
carcinoma,neuroendocrine;lung;surgery;prognosis

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 陈野野;田震寰;周小昀;张晔;刘洪生;李单青;
CHEN Ye-ye;TIAN Zhen-huan;ZHOU Xiao-yun;ZHANG Ye;LIU Hong-sheng;LI Shan-qing;Department of Thoracic Surgery,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences &Peking Union Medical College;

参考文献(References)：

• [1]Sanchez de Cos Escuin J.Diagnosis and treatment of neuroendocrine lung tumors[J].Arch Bronconeumol,2014,50:392-396.
• [2]Pusceddu S,Lo Russo G,Macerelli M,et al.Diagnosis and management of typical and atypical lung carcinoids[J].Crit Rev Oncol Hematol,2016,100:167-176.
• [3]Travis WD BE,Burke AP,Marx A,et al.WHO classification of tumours of the lung,pleura,thymus and heart[M].4th ed.Geneva,Switzerland:WHO Press,2015:9-97.
• [4]Han B,Sun JM,Ahn JS,et al.Clinical outcomes of atypical carcinoid tumors of the lung and thymus:7-year experience of a rare malignancy at single institute[J].Med Oncol,2013,30:479.
• [5]Lababede O,Meziane M,Rice T.Seventh edition of the cancer staging manual and stage grouping of lung cancer:quick reference chart and diagrams[J].Chest,2011,139:183-189.
• [6]Yao JC,Hassan M,Phan A,et al.One hundred years after“carcinoid”:epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States[J].J Clin Oncol,2008,26:3063-3072.
• [7]Wolin EM.Advances in the diagnosis and management of well-differentiated and intermediate-differentiated neuroendocrine tumors of the lung[J].Chest,2017,151:1141-1146..
• [8]陈野野,李单青,田震寰,等.肺大细胞神经内分泌癌手术治疗及预后因素[J].协和医学杂志,2016,7:98-103.
• [9]Chen YY,Li SQ,Liu HS,et al.Ectopic adrenocorticotropic hormone syndrome caused by neuroendocrine tumors of the thymus:30-year experience with 16 patients at a single institute in the People's Republic of China[J].Onco Targets Ther,2016,9:2193-2201.
• [10]李力,陈野野,李单青,等.肺部病变所致异位促肾上腺皮质激素综合征的临床诊治经验[J].中国肿瘤临床与康复,2014,21:1227-1231.
• [11]Chong S,Lee KS,Chung MJ,et al.Neuroendocrine tumors of the lung:clinical,pathologic,and imaging findings[J].Radiographics,2006,26:41-58.
• [12]Franks TJ,Galvin JR.Lung tumors with neuroendocrine morphology:essential radiologic and pathologic features[J].Arch Pathol Lab Med,2008,132:1055-1061.
• [13]Akata S,Okada S,Maeda J,et al.Computed tomographic findings of large cell neuroendocrine carcinoma of the lung[J].2007,31:379-384.
• [14]Travis WD.Pathology and diagnosis of neuroendocrine tumors:lung neuroendocrine[J].Thorac Surg Clin,2014,24:257-266.
• [15]Wolin EM.Challenges in the diagnosis and management of well-differentiated neuroendocrine tumors of the lung(typical and atypical carcinoid):current status and future considerations[J].Oncologist,2015,20:1123-1131.
• [16]Filosso PL,Ferolla P,Guerrera F,et al.Multidisciplinary management of advanced lung neuroendocrine tumors[J].J Thorac Dis,2015,7(Suppl 2):S163-S171.
• [17]Caplin ME,Baudin E,Ferolla P,et al.Pulmonary neuroendocrine(carcinoid)tumors:European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids[J].Ann Oncol,2015,26:1604-1620.
• [18]Rea F,Rizzardi G,Zuin A,et al.Outcome and surgical strategy in bronchial carcinoid tumors:single institution experience with 252 patients[J].Eur J Cardiothorac Surg,2007,31:186-191.
• [19]Garcia-Yuste M,Matilla JM,Cueto A,et al.Typical and atypical carcinoid tumours:analysis of the experience of the Spanish Multi-centric Study of Neuroendocrine Tumours of the Lung[J].Eur J Cardio-thorac Surg,2007,31:192-197.
• [20]Nussbaum DP,Speicher PJ,Gulack BC,et al.Defining the role of adjuvant chemotherapy after lobectomy for typical bronchopulmonary carcinoid tumors[J].Ann Thorac Surgery,2015,99:428-434.
• [21]Kyriss T,Maier S,Veit S,et al.Carcinoid lung tumors:long-term results from 111 resections[J].Thorac Surg Sci,2006,3:Doc03.
• [22]Yao JC,Fazio N,Singh S,et al.Everolimus for the treatment of advanced,non-functional neuroendocrine tumours of the lung or gastrointestinal tract(RADIANT-4):a randomised,placebo-controlled,phase 3 study[J].Lancet,2016,387:968-977.